Dr Hilary says Johnson & Johnson jab blood clots are 'rare'
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Johnson & Johnson’s Janssen COVID-19 vaccine is the latest vaccine to come under scrutiny after Belgium pulled the plug on rolling it out for people under the age of 41 following the death of a woman from severe side-effects. “The Inter-ministerial conference has decided to temporarily administer Janssen’s vaccine to the general population from the age of 41 years, pending a more detailed benefit-risk analysis by the EMA,” the Belgian health ministers said in a statement. The EMA is the European Union’s European Medicine’s Agency.
At the time of the announcement, there was no immediate comment from J&J.
The woman – who was under the age of 40 – died on May 21, after being admitted to hospital with severe thrombosis and platelet deficiency, the statement said.
She was vaccinated through her employer and outside of the official Belgian vaccination campaign.
Deliveries of J&J’s vaccine in Belgium have so far been limited to about 40,000 units, with 80 percent of the doses administered so far to people over 45 years old, the statement said.
J&J said on April 20 it would resume rolling out its COVID-19 vaccine in Europe with a warning on its label, after requesting countries, including Belgium, to pause its use amid concerns about possible links to rare blood clots.
J&J has said that no clear causal relationship has been established between the clots and its shot while the EMA has maintained that the benefits of the shot outweigh any risks.
Meanwhile, Belgium has asked for advice from the EMA to evaluate the link between the woman’s death and the J&J vaccine.
It did not confirm when it expected EMA’s final opinion on it.
Source: Read Full Article